Company news

Silo Pharma, Inc. news in 2022

Silo Pharma, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

December 29, 2022

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

November 20, 2022

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

November 10, 2022

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

October 2, 2022

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

September 29, 2022

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

September 14, 2022

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

July 26, 2022

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

July 11, 2022

Silo Pharma Expands License Agreement and Patent Portfolio

June 22, 2022

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

May 18, 2022

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

April 19, 2022

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

February 2, 2022

Decks in 2022